1. Home
  2. CRDF vs DIT Comparison

CRDF vs DIT Comparison

Compare CRDF & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Logo AMCON Distributing Company

DIT

AMCON Distributing Company

SELL

Current Price

$58.99

Market Cap

64.4M

ML Signal

SELL

Company Overview

Basic Information
Metric
CRDF
DIT
Founded
1999
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Food Distributors
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
64.4M
IPO Year
2012
1996

Fundamental Metrics

Financial Performance
Metric
CRDF
DIT
Price
$0.87
$58.99
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $5.14
N/A
AVG Volume (30 Days)
★ 1.0M
668.0
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
★ 1.14%
EPS Growth
27.37
★ 173.91
EPS
N/A
★ 2.52
Revenue
$365,993.00
★ $1,392,388,157.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$23.41
Revenue Growth
★ 49.61
5.30
52 Week Low
$0.71
$58.62
52 Week High
$3.31
$118.50

Technical Indicators

Market Signals
Indicator
CRDF
DIT
Relative Strength Index (RSI) N/A 39.92
Support Level N/A N/A
Resistance Level N/A $70.51
Average True Range (ATR) 0.00 1.37
MACD 0.00 -0.03
Stochastic Oscillator 0.00 5.76

Price Performance

Historical Comparison
CRDF
DIT

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

About DIT AMCON Distributing Company

Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.

Share on Social Networks: